{"id":55552,"date":"2022-12-23T14:57:10","date_gmt":"2022-12-23T14:57:10","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=55552"},"modified":"2022-12-23T14:57:10","modified_gmt":"2022-12-23T14:57:10","slug":"sudeep-gupta-sabcs-2022-addition-of-platinum-to-neoadjuvant-chemotherapy-in-patients-with-triple-negative-breast-cancer-a-phase-iii-randomized-controlled-trial","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/breast-cancer\/conference-hub\/sudeep-gupta-sabcs-2022-addition-of-platinum-to-neoadjuvant-chemotherapy-in-patients-with-triple-negative-breast-cancer-a-phase-iii-randomized-controlled-trial\/","title":{"rendered":"Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial"},"content":{"rendered":"

The impact of adding platinum on long-term outcomes in triple-negative breast cancer\u00a0<\/span>(TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak with Dr Sudeep Gupta <\/b>(Tata Memorial Hospital, Mumbai, India) who discusses the rationale for adding carboplatin to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer and<\/span>\u00a0gives an overview of his phase III study.<\/p>\n

The abstract entitled \u2018Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial<\/span><\/span>\u2019 was presented at San Antonio Breast Cancer Symposium\u00a0(SABCS)<\/a>, 06\u201310, December, 2022.<\/span><\/p>\n

Questions<\/b>:<\/span><\/p>\n

    \n
  1. What is the rationale for adding carboplatin to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC)? (0:22)
    \n<\/span><\/li>\n
  2. What were the methodology and eligibility criteria of your study evaluating this regimen? (1:26)
    \n<\/span><\/li>\n
  3. What were the primary and secondary outcome measures and how well were they achieved? (3:25)
    \n<\/span><\/li>\n
  4. What was the safety and tolerability of this regimen? (07:07)
    \n<\/span><\/li>\n
  5. What will be the impact of these findings on the standard of care for TNBC? (8:10)<\/span><\/li>\n<\/ol>\n

    Disclosures<\/b>: Sudeep Gupta has nothing to disclose in relation to this video interview.<\/span><\/p>\n

    Support<\/b>: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen<\/span><\/p>\n

    Filmed as a highlight of <\/i><\/b>SABCS 2022<\/i><\/b><\/a><\/p>\n

    Access more content on Breast Cancer<\/a><\/i><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    The impact of adding platinum on long-term outcomes in triple-negative breast cancer\u00a0(TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]<\/p>\n","protected":false},"featured_media":55592,"template":"","class_list":["post-55552","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-breast-cancer","video_categories-sabcs-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/55552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":4,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/55552\/revisions"}],"predecessor-version":[{"id":55593,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/55552\/revisions\/55593"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/55592"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=55552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}